{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:15:14Z","timestamp":1791353714278,"version":"4.3.1"},"reference-count":112,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2017,3,7]],"date-time":"2017-03-07T00:00:00Z","timestamp":1488844800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Protein Cell"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s13238-017-0386-6","type":"journal-article","created":{"date-parts":[[2017,3,7]],"date-time":"2017-03-07T08:02:18Z","timestamp":1488873738000},"page":"3-14","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":163,"title":["In vitro-engineered non-antibody protein therapeutics"],"prefix":"10.1093","volume":"9","author":[{"given":"Rudo","family":"Simeon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhilei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,3,7]]},"reference":[{"key":"386_CR1","unstructured":"A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration. https:\/\/www.clinicaltrialsgov\/ct2\/show\/study\/NCT02181517 ."},{"key":"386_CR2","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/cbic.201402704","volume":"16","author":"TL Aboye","year":"2015","unstructured":"Aboye TL, Stromstedt AA, Gunasekera S, Bruhn JG, El-Seedi H, Rosengren KJ, Goransson U (2015) A cactus-derived toxin-like cystine knot Peptide with selective antimicrobial activity. Chembiochem 16:1068\u20131077","journal-title":"Chembiochem"},{"key":"386_CR3","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2174\/138920110792246609","volume":"11","author":"S Ahlgren","year":"2010","unstructured":"Ahlgren S, Tolmachev V (2010) Radionuclide molecular imaging using Affibody molecules. Curr Pharm Biotechnol 11:581\u2013589","journal-title":"Curr Pharm Biotechnol"},{"key":"386_CR4","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1021\/bc300184m","volume":"23","author":"A Angelini","year":"2012","unstructured":"Angelini A, Diderich P, Morales-Sanfrutos J, Thurnheer S, Hacker D, Menin L, Heinis C (2012) Chemical macrocyclization of peptides fused to antibody Fc fragments. Bioconjug Chem 23:1856\u20131863","journal-title":"Bioconjug Chem"},{"key":"386_CR5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/978-3-319-32805-8_7","volume":"917","author":"O Avrutina","year":"2016","unstructured":"Avrutina O (2016) Synthetic cystine-knot miniproteins\u2014valuable scaffolds for polypeptide engineering. Adv Exp Med Biol 917:121\u2013144","journal-title":"Adv Exp Med Biol"},{"key":"386_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/17425240802650568","volume":"6","author":"P Bailon","year":"2009","unstructured":"Bailon P, Won CY (2009) PEG-modified biopharmaceuticals. Expert Opin Drug Deliv 6:1\u201316","journal-title":"Expert Opin Drug Deliv"},{"key":"386_CR7","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00296-006-0183-7","volume":"27","author":"NK Bender","year":"2007","unstructured":"Bender NK, Heilig CE, Droll B, Wohlgemuth J, Armbruster FP, Heilig B (2007) Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int 27:269\u2013274","journal-title":"Rheumatol Int"},{"key":"386_CR8","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0022-2836(03)00896-9","volume":"332","author":"HK Binz","year":"2003","unstructured":"Binz HK, Stumpp MT, Forrer P, Amstutz P, Pluckthun A (2003) Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. J Mol Biol 332:489\u2013503","journal-title":"J Mol Biol"},{"key":"386_CR9","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1432-1033.1992.tb16654.x","volume":"204","author":"W Bode","year":"1992","unstructured":"Bode W, Huber R (1992) Natural protein proteinase inhibitors and their interaction with proteinases. Eur J Biochem 204:433\u2013451","journal-title":"Eur J Biochem"},{"key":"386_CR10","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nbt0697-553","volume":"15","author":"ET Boder","year":"1997","unstructured":"Boder ET, Wittrup KD (1997) Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol 15:553\u2013557","journal-title":"Nat Biotechnol"},{"key":"386_CR11","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/prot.340170405","volume":"17","author":"P Bork","year":"1993","unstructured":"Bork P (1993) Hundreds of ankyrin-like repeats in functionally diverse proteins: mobile modules that cross phyla horizontally? Proteins 17:363\u2013374","journal-title":"Proteins"},{"key":"386_CR12","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.lfs.2010.03.015","volume":"86","author":"AP Bryant","year":"2010","unstructured":"Bryant AP, Busby RW, Bartolini WP, Cordero EA, Hannig G, Kessler MM, Pierce CM, Solinga RM, Tobin JV, Mahajan-Miklos S et al (2010) Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sci 86:760\u2013765","journal-title":"Life Sci"},{"key":"386_CR13","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0169-409X(03)00108-X","volume":"55","author":"P Caliceti","year":"2003","unstructured":"Caliceti P, Veronese FM (2003) Pharmacokinetic and biodistribution properties of poly(ethylene glycol)\u2013protein conjugates. Adv Drug Deliv Rev 55:1261\u20131277","journal-title":"Adv Drug Deliv Rev"},{"issue":"697\u2013704","key":"386_CR14","first-page":"e692","volume":"155","author":"PA Campochiaro","year":"2013","unstructured":"Campochiaro PA, Channa R, Berger BB, Heier JS, Brown DM, Fiedler U, Hepp J, Stumpp MT (2013) Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I\/II study. Am J Ophthalmol 155(697\u2013704):e692","journal-title":"Am J Ophthalmol"},{"key":"386_CR15","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.1021\/bi052628y","volume":"45","author":"C Chaudhury","year":"2006","unstructured":"Chaudhury C, Brooks CL, Carter DC, Robinson JM, Anderson CL (2006) Albumin binding to FcRn: distinct from the FcRn\u2013IgG interaction. Biochemistry 45:4983\u20134990","journal-title":"Biochemistry"},{"key":"386_CR16","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1146\/annurev-chembioeng-061010-114300","volume":"2","author":"VP Chauhan","year":"2011","unstructured":"Chauhan VP, Stylianopoulos T, Boucher Y, Jain RK (2011) Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu Rev Chem Biomol Eng 2:281\u2013298","journal-title":"Annu Rev Chem Biomol Eng"},{"key":"386_CR17","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1038\/ajg.2012.254","volume":"107","author":"WD Chey","year":"2012","unstructured":"Chey WD, Lembo AJ, Lavins BJ, Shiff SJ, Kurtz CB, Currie MG, MacDougall JE, Jia XD, Shao JZ, Fitch DA et al (2012) Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 107:1702\u20131712","journal-title":"Am J Gastroenterol"},{"key":"386_CR18","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa0905079","volume":"363","author":"M Cicardi","year":"2010","unstructured":"Cicardi M, Levy RJ, McNeil DL, Li HH, Sheffer AL, Campion M, Horn PT, Pullman WE (2010) Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 363:523\u2013531","journal-title":"N Engl J Med"},{"key":"386_CR19","doi-asserted-by":"crossref","first-page":"5965","DOI":"10.1021\/bi049711q","volume":"43","author":"ML Colgrave","year":"2004","unstructured":"Colgrave ML, Craik DJ (2004) Thermal, chemical, and enzymatic stability of the cyclotide kalata B1: the importance of the cyclic cystine knot. Biochemistry 43:5965\u20135975","journal-title":"Biochemistry"},{"key":"386_CR20","first-page":"66","volume":"1","author":"MP Cooke","year":"1989","unstructured":"Cooke MP, Perlmutter RM (1989) Expression of a novel form of the fyn proto-oncogene in hematopoietic cells. New Biol 1:66\u201374","journal-title":"New Biol"},{"key":"386_CR21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00018-009-0159-3","volume":"67","author":"DJ Craik","year":"2010","unstructured":"Craik DJ, Mylne JS, Daly NL (2010) Cyclotides: macrocyclic peptides with applications in drug design and agriculture. Cell Mol Life Sci 67:9\u201316","journal-title":"Cell Mol Life Sci"},{"key":"386_CR22","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/ni.3515","volume":"17","author":"W Dejnirattisai","year":"2016","unstructured":"Dejnirattisai W, Supasa P, Wongwiwat W, Rouvinski A, Barba-Spaeth G, Duangchinda T, Sakuntabhai A, Cao-Lormeau VM, Malasit P, Rey FA et al (2016) Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nat Immunol. 17:1102\u20131108","journal-title":"Nat Immunol."},{"key":"386_CR23","doi-asserted-by":"crossref","first-page":"35035","DOI":"10.1074\/jbc.M205854200","volume":"277","author":"MS Dennis","year":"2002","unstructured":"Dennis MS, Zhang M, Meng YG, Kadkhodayan M, Kirchhofer D, Combs D, Damico LA (2002) Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J Biol Chem 277:35035\u201335043","journal-title":"J Biol Chem"},{"key":"386_CR24","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1186\/1471-2407-8-352","volume":"8","author":"SP Dineen","year":"2008","unstructured":"Dineen SP, Sullivan LA, Beck AW, Miller AF, Carbon JG, Mamluk R, Wong H, Brekken RA (2008) The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer. BMC Cancer 8:352","journal-title":"BMC Cancer"},{"key":"386_CR25","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/978-1-60761-944-4_21","volume":"687","author":"B Dreier","year":"2011","unstructured":"Dreier B, Pluckthun A (2011) Ribosome display: a technology for selecting and evolving proteins from large libraries. Methods Mol Biol 687:283\u2013306","journal-title":"Methods Mol Biol"},{"key":"386_CR26","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jcf.2012.02.003","volume":"11","author":"FK Dunlevy","year":"2012","unstructured":"Dunlevy FK, Martin SL, de Courcey F, Elborn JS, Ennis M (2012) Anti-inflammatory effects of DX-890, a human neutrophil elastase inhibitor. J Cyst Fibros 11:300\u2013304","journal-title":"J Cyst Fibros"},{"key":"386_CR27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4161\/19420862.2015.989042","volume":"7","author":"DM Ecker","year":"2015","unstructured":"Ecker DM, Jones SD, Levine HL (2015) The therapeutic monoclonal antibody market. mAbs 7:9\u201314","journal-title":"mAbs"},{"key":"386_CR28","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jconrel.2011.09.069","volume":"157","author":"B Elsadek","year":"2012","unstructured":"Elsadek B, Kratz F (2012) Impact of albumin on drug delivery\u2013new applications on the horizon. J Control Release 157:4\u201328","journal-title":"J Control Release"},{"key":"386_CR29","doi-asserted-by":"crossref","first-page":"e312","DOI":"10.1111\/j.1365-2982.2009.01385.x","volume":"22","author":"H Eutamene","year":"2010","unstructured":"Eutamene H, Bradesi S, Larauche M, Theodorou V, Beaufrand C, Ohning G, Fioramonti J, Cohen M, Bryant AP, Kurtz C et al (2010) Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain. Neurogastroenterol Motil 22:e312\u2013e384","journal-title":"Neurogastroenterol Motil"},{"key":"386_CR30","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1002\/anie.200353242","volume":"43","author":"R Fasan","year":"2004","unstructured":"Fasan R, Dias RLA, Moehle K, Zerbe O, Vrijbloed JW, Obrecht D, Robinson JA (2004) Using a \u03b2-hairpin to mimic an \u03b1-helix: cyclic peptidomimetic inhibitors of the p53\u2013HDM2 protein-protein interaction. Angew Chem Int Ed 43:2109\u20132112","journal-title":"Angew Chem Int Ed"},{"key":"386_CR31","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/nbt785","volume":"21","author":"MJ Feldhaus","year":"2003","unstructured":"Feldhaus MJ, Siegel RW, Opresko LK, Coleman JR, Feldhaus JMW, Yeung YA, Cochran JR, Heinzelman P, Colby D, Swers J et al (2003) Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library. Nat Biotech 21:163\u2013170","journal-title":"Nat Biotech"},{"key":"386_CR32","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jmb.2010.03.002","volume":"398","author":"J Feldwisch","year":"2010","unstructured":"Feldwisch J, Tolmachev V, Lendel C, Herne N, Sjoberg A, Larsson B, Rosik D, Lindqvist E, Fant G, Hoiden-Guthenberg I et al (2010) Design of an optimized scaffold for affibody molecules. J Mol Biol 398:232\u2013247","journal-title":"J Mol Biol"},{"key":"386_CR33","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/01.iae.0000242842.14624.e7","volume":"26","author":"N Ferrara","year":"2006","unstructured":"Ferrara N, Damico L, Shams N, Lowman H, Kim R (2006) Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26:859\u2013870","journal-title":"Retina"},{"key":"386_CR34","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.sbi.2007.08.012","volume":"17","author":"SA Gai","year":"2007","unstructured":"Gai SA, Wittrup KD (2007) Yeast surface display for protein engineering and characterization. Curr Opin Struct Biol 17:467\u2013473","journal-title":"Curr Opin Struct Biol"},{"key":"386_CR35","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/B978-0-12-396962-0.00007-0","volume":"503","author":"M Gebauer","year":"2012","unstructured":"Gebauer M, Skerra A (2012) Anticalins small engineered binding proteins based on the lipocalin scaffold. Method Enzymol 503:157\u2013188","journal-title":"Method Enzymol"},{"key":"386_CR36","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.chembiol.2005.12.009","volume":"13","author":"EV Getmanova","year":"2006","unstructured":"Getmanova EV, Chen Y, Bloom L, Gokemeijer J, Shamah S, Warikoo V, Wang J, Ling V, Sun L (2006) Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro. Chem Biol 13:549\u2013556","journal-title":"Chem Biol"},{"key":"386_CR37","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10456-015-9490-5","volume":"19","author":"H Gille","year":"2016","unstructured":"Gille H, Hulsmeyer M, Trentmann S, Matschiner G, Christian HJ, Meyer T, Amirkhosravi A, Audoly LP, Hohlbaum AM, Skerra A (2016) Functional characterization of a VEGF-A-targeting Anticalin, prototype of a novel therapeutic human protein class. Angiogenesis 19:79\u201394","journal-title":"Angiogenesis"},{"key":"386_CR38","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1074\/jbc.M609211200","volume":"282","author":"D Grabulovski","year":"2007","unstructured":"Grabulovski D, Kaspar M, Neri D (2007) A novel, non-immunogenic Fyn SH3-derived binding protein with tumor vascular targeting properties. J Biol Chem 282:3196\u20133204","journal-title":"J Biol Chem"},{"key":"386_CR39","doi-asserted-by":"crossref","first-page":"D314","DOI":"10.1093\/nar\/gkm939","volume":"36","author":"J Gracy","year":"2008","unstructured":"Gracy J, Le-Nguyen D, Gelly JC, Kaas Q, Heitz A, Chiche L (2008) KNOTTIN: the knottin or inhibitor cystine knot scaffold in 2007. Nucleic Acids Res 36:D314\u2013D319","journal-title":"Nucleic Acids Res"},{"key":"386_CR40","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.jmb.2008.06.051","volume":"381","author":"BJ Hackel","year":"2008","unstructured":"Hackel BJ, Kapila A, Wittrup KD (2008) Picomolar affinity fibronectin domains engineered utilizing loop length diversity, recursive mutagenesis, and loop shuffling. J Mol Biol 381:1238\u20131252","journal-title":"J Mol Biol"},{"key":"386_CR41","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/protein\/gzm067","volume":"21","author":"LJ Holt","year":"2008","unstructured":"Holt LJ, Basran A, Jones K, Chorlton J, Jespers LS, Brewis ND, Tomlinson IM (2008) Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. Protein Eng Des Sel 21:283\u2013288","journal-title":"Protein Eng Des Sel"},{"key":"386_CR42","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1110\/ps.051817606","volume":"15","author":"RJ Hosse","year":"2006","unstructured":"Hosse RJ, Rothe A, Power BE (2006) A new generation of protein display scaffolds for molecular recognition. Protein Sci 15:14\u201327","journal-title":"Protein Sci"},{"issue":"33\u201338","key":"386_CR43","first-page":"27","volume":"14","author":"W Humphrey","year":"1996","unstructured":"Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph\u00a014(33\u201338):27\u201338","journal-title":"J Mol Graph"},{"key":"386_CR44","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.sbi.2014.05.011","volume":"27","author":"C Jost","year":"2014","unstructured":"Jost C, Pluckthun A (2014) Engineered proteins with desired specificity: DARPins, other alternative scaffolds and bispecific IgGs. Curr Opin Struct Biol 27:102\u2013112","journal-title":"Curr Opin Struct Biol"},{"key":"386_CR45","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1038\/leu.2013.266","volume":"27","author":"D Karpova","year":"2013","unstructured":"Karpova D, Dauber K, Spohn G, Chudziak D, Wiercinska E, Schulz M, Pettit AR, Levesque JP, Romagnoli B, Patel K et al (2013) The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor. Leukemia 27:2322\u20132331","journal-title":"Leukemia"},{"key":"386_CR46","doi-asserted-by":"crossref","first-page":"443","DOI":"10.4161\/mabs.1.5.9448","volume":"1","author":"B Kelley","year":"2009","unstructured":"Kelley B (2009) Industrialization of mAb production technology the bioprocessing industry at a crossroads. mAbs 1:443\u2013452","journal-title":"mAbs"},{"key":"386_CR47","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cbpa.2016.08.022","volume":"34","author":"JR Kintzing","year":"2016","unstructured":"Kintzing JR, Cochran JR (2016a) Engineered knottin peptides as diagnostics, therapeutics, and drug delivery vehicles. Curr Opin Chem Biol 34:143\u2013150","journal-title":"Curr Opin Chem Biol"},{"key":"386_CR48","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cbpa.2016.08.022","volume":"34","author":"JR Kintzing","year":"2016","unstructured":"Kintzing JR, Cochran JR (2016b) Engineered knottin peptides as diagnostics, therapeutics, and drug delivery vehicles. Curr Opin Chem Biol 34:143\u2013150","journal-title":"Curr Opin Chem Biol"},{"key":"386_CR49","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.coph.2009.05.004","volume":"9","author":"H Kolmar","year":"2009","unstructured":"Kolmar H (2009) Biological diversity and therapeutic potential of natural and engineered cystine knot miniproteins. Curr Opin Pharmacol 9:608\u2013614","journal-title":"Curr Opin Pharmacol"},{"key":"386_CR50","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.copbio.2011.06.012","volume":"22","author":"RE Kontermann","year":"2011","unstructured":"Kontermann RE (2011) Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol 22:868\u2013876","journal-title":"Curr Opin Biotechnol"},{"key":"386_CR51","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1006\/mcne.1994.1026","volume":"5","author":"R Kristipati","year":"1994","unstructured":"Kristipati R, N\u00e1dasdi L, Tarczy-Hornoch K, Lau K, Miljanich GP, Ramachandran J, Bell JR (1994) Characterization of the binding of omega-conopeptides to different classes of non-L-type neuronal calcium channels. Mol Cell Neurosci 5:219\u2013228","journal-title":"Mol Cell Neurosci"},{"key":"386_CR52","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/apt.12604","volume":"39","author":"P Layer","year":"2014","unstructured":"Layer P, Stanghellini V (2014) Review article: Linaclotide for the management of irritable bowel syndrome with constipation. Aliment Pharmacol Ther 39:371\u2013384","journal-title":"Aliment Pharmacol Ther"},{"key":"386_CR53","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.anai.2010.04.012","volume":"104","author":"RJ Levy","year":"2010","unstructured":"Levy RJ, Lumry WR, McNeil DL, Li HH, Campion M, Horn PT, Pullman WE (2010) EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol 104:523\u2013529","journal-title":"Ann Allergy Asthma Immunol"},{"key":"386_CR54","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/protein\/gzq097","volume":"24","author":"D Lipovsek","year":"2011","unstructured":"Lipovsek D (2011) Adnectins: engineered target-binding protein therapeutics. Protein Eng Des Sel 24:3\u20139","journal-title":"Protein Eng Des Sel"},{"key":"386_CR55","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jim.2004.04.008","volume":"290","author":"D Lipovsek","year":"2004","unstructured":"Lipovsek D, Pluckthun A (2004) In-vitro protein evolution by ribosome display and mRNA display. J Immunol Methods 290:51\u201367","journal-title":"J Immunol Methods"},{"key":"386_CR56","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1016\/j.nmd.2016.06.036","volume":"26","author":"M Madireddi","year":"2016","unstructured":"Madireddi M, Malone H, Kukral D, Chimalakonda A, Kozhich A, Xiling Y, Swain J, Yamniuk A, Ahlijanian M (2016) BMS-986089 is a high affinity anti-myostatin adnectin that increases muscle volume in three preclinical species. Neuromuscul Disord 26:S94\u2013S95","journal-title":"Neuromuscul Disord"},{"key":"386_CR57","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/0041-0101(94)00186-C","volume":"33","author":"B Maillere","year":"1995","unstructured":"Maillere B, Mourier G, Herve M, Cotton J, Leroy S, Menez A (1995) Immunogenicity of a disulphide-containing neurotoxin: presentation to T-cells requires a reduction step. Toxicon 33:475\u2013482","journal-title":"Toxicon"},{"key":"386_CR58","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1124\/jpet.114.214221","volume":"350","author":"T Mitchell","year":"2014","unstructured":"Mitchell T, Chao G, Sitkoff D, Lo F, Monshizadegan H, Meyers D, Low S, Russo K, DiBella R, Denhez F et al (2014) Pharmacologic profile of the Adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering. J Pharmacol Exp Ther 350:412\u2013424","journal-title":"J Pharmacol Exp Ther"},{"key":"386_CR59","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1182\/blood.V126.23.536.536","volume":"126","author":"U Moebius","year":"2015","unstructured":"Moebius U, Feuerer W, Fenzl E, van Swelm R, Swinkels DW, Hohlbaum A (2015) A Phase I study investigating the safety, tolerability, pharmacokinetics and pharmacodynamic activity of the hepcidin antagonist PRS-080#022. Results from a randomized, placebo controlled, double-blind study following single administration to healthy subjects. Blood 126:536","journal-title":"Blood"},{"key":"386_CR60","unstructured":"Molecular Partners (2015). http:\/\/www.molecularpartners.com\/preliminary-phase-i-results-demonstrate-potential-utility-of-darpins-in-anticancer-treatment\/ ."},{"key":"386_CR61","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/B978-0-12-396962-0.00009-4","volume":"503","author":"SJ Moore","year":"2012","unstructured":"Moore SJ, Cochran JR (2012) Engineering knottins as novel binding agents. Methods Enzymol 503:223\u2013251","journal-title":"Methods Enzymol"},{"key":"386_CR62","doi-asserted-by":"crossref","first-page":"e83232","DOI":"10.1371\/journal.pone.0083232","volume":"8","author":"K Mross","year":"2013","unstructured":"Mross K, Richly H, Fischer R, Scharr D, Buchert M, Stern A, Gille H, Audoly LP, Scheulen ME (2013a) First-in-human phase I study of PRS-050 (Angiocal), an Anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors. PLoS ONE 8:e83232","journal-title":"PLoS ONE"},{"key":"386_CR63","doi-asserted-by":"crossref","first-page":"e83232","DOI":"10.1371\/journal.pone.0083232","volume":"8","author":"K Mross","year":"2013","unstructured":"Mross K, Richly H, Fischer R, Scharr D, B\u00fcchert M, Stern A, Gille H, Audoly LP, Scheulen ME (2013b) First-in-human phase I study of PRS-050 (Angiocal), an Anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors. PLoS ONE 8:e83232","journal-title":"PLoS ONE"},{"key":"386_CR64","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/protein\/gzl011","volume":"19","author":"A Nguyen","year":"2006","unstructured":"Nguyen A, Reyes AE II, Zhang M, McDonald P, Wong WL, Damico LA, Dennis MS (2006) The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of affinity for albumin. Protein Eng Des Sel 19:291\u2013297","journal-title":"Protein Eng Des Sel"},{"key":"386_CR65","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/nbt0897-772","volume":"15","author":"K Nord","year":"1996","unstructured":"Nord K, Gunneriusson E, Ringdahl J, Stahl S, Uhlen M, Nygren P-A (1996) Binding proteins selected from combinatorial libraries of an [alpha]-helical bacterial receptor domain. Nat Biotech 15:772\u2013777","journal-title":"Nat Biotech"},{"key":"386_CR66","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/nbt0897-772","volume":"15","author":"K Nord","year":"1997","unstructured":"Nord K, Gunneriusson E, Ringdahl J, Stahl S, Uhlen M, Nygren PA (1997) Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nat Biotechnol 15:772\u2013777","journal-title":"Nat Biotechnol"},{"key":"386_CR67","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0140-6736(97)09137-X","volume":"351","author":"J Nussberger","year":"1998","unstructured":"Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A (1998) Plasma bradykinin in angio-oedema. The Lancet 351:1693\u20131697","journal-title":"The Lancet"},{"key":"386_CR68","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1111\/j.1742-4658.2008.06438.x","volume":"275","author":"PA Nygren","year":"2008","unstructured":"Nygren PA (2008) Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold. FEBS J 275:2668\u20132676","journal-title":"FEBS J"},{"key":"386_CR69","doi-asserted-by":"crossref","unstructured":"Paul L, Carlin E, Jenkins M (2016) Dengue virus antibodies enhance Zika virus infection. bioRxiv ( http:\/\/www.biorxivorg\/content\/early\/2016\/04\/25\/050112 ).","DOI":"10.1101\/050112"},{"key":"386_CR70","unstructured":"Pieris Pharmaceuticals I (2015). http:\/\/www.pieris.com\/news-and-events\/press-releases\/detail\/524\/pieris-pharmaceuticals-presents-clinical-data-for-its ."},{"key":"386_CR71","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1146\/annurev-pharmtox-010611-134654","volume":"55","author":"A Pluckthun","year":"2015","unstructured":"Pluckthun A (2015) Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy. Annu Rev Pharmacol Toxicol 55:489\u2013511","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"386_CR72","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.str.2011.11.016","volume":"20","author":"V Ramamurthy","year":"2012","unstructured":"Ramamurthy V, Krystek SR Jr, Bush A, Wei A, Emanuel SL, Das Gupta R, Janjua A, Cheng L, Murdock M, Abramczyk B et al (2012) Structures of adnectin\/protein complexes reveal an expanded binding footprint. Structure\u00a020:259\u2013269","journal-title":"Structure"},{"key":"386_CR73","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jpainsymman.2005.10.003","volume":"31","author":"RL Rauck","year":"2006","unstructured":"Rauck RL, Wallace MS, Leong MS, MineHart M, Webster LR, Charapata SG, Abraham JE, Buffington DE, Ellis D, Kartzinel R et al (2006) A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manag 31:393\u2013406","journal-title":"J Pain Symptom Manag"},{"key":"386_CR74","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/19420862.2016.1269580","volume":"9","author":"JM Reichert","year":"2017","unstructured":"Reichert JM (2017) Antibodies to watch in 2017. mAbs 9:167\u2013181","journal-title":"mAbs"},{"key":"386_CR75","doi-asserted-by":"crossref","unstructured":"Reichert JM, Beck A, Lugovskoy AA, Wurch T, Coats S, Brezski RJ (2014) 9th Annual European antibody congress, November 11\u201313, 2013, Geneva, Switzerland. mAbs 6:309\u2013326","DOI":"10.4161\/mabs.27903"},{"key":"386_CR76","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1073\/pnas.89.6.2429","volume":"89","author":"BL Roberts","year":"1992","unstructured":"Roberts BL, Markland W, Ley AC, Kent RB, White DW, Guterman SK, Ladner RC (1992) Directed evolution of a protein: selection of potent neutrophil elastase inhibitors displayed on M13 fusion phage. Proc Natl Acad Sci USA 89:2429\u20132433","journal-title":"Proc Natl Acad Sci USA"},{"key":"386_CR77","doi-asserted-by":"crossref","first-page":"B25","DOI":"10.1158\/1535-7163.TARG-15-B25","volume":"14","author":"J Rodon","year":"2015","unstructured":"Rodon J, Omlin A, Herbschleb KH, Garcia-Corbacho J, Steiner J, Dolado I, Zitt C, Feurstein D, Turner D, Dawson KM et al (2015) Abstract B25: First-in-human Phase I study to evaluate MP0250, a DARPin blocking HGF and VEGF, in patients with advanced solid tumors. Mol Cancer Ther 14:B25","journal-title":"Mol Cancer Ther"},{"key":"386_CR78","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2967\/jnumed.115.169342","volume":"57","author":"M Sandstrom","year":"2016","unstructured":"Sandstrom M, Lindskog K, Velikyan I, Wennborg A, Feldwisch J, Sandberg D, Tolmachev V, Orlova A, Sorensen J, Carlsson J et al (2016) Biodistribution and radiation dosimetry of the Anti-HER2 affibody molecule 68Ga-ABY-025 in breast cancer patients. J Nucl Med 57:867\u2013871","journal-title":"J Nucl Med"},{"key":"386_CR79","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s10637-014-0186-2","volume":"33","author":"D Schiff","year":"2015","unstructured":"Schiff D, Kesari S, de Groot J, Mikkelsen T, Drappatz J, Coyle T, Fichtel L, Silver B, Walters I, Reardon D (2015) Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma. Investig New Drugs 33:247\u2013253","journal-title":"Investig New Drugs"},{"key":"386_CR80","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.jmb.2013.10.026","volume":"426","author":"J Schilling","year":"2014","unstructured":"Schilling J, Schoppe J, Pluckthun A (2014) From DARPins to LoopDARPins: novel LoopDARPin design allows the selection of low picomolar binders in a single round of ribosome display. J Mol Biol 426:691\u2013721","journal-title":"J Mol Biol"},{"key":"386_CR81","doi-asserted-by":"crossref","first-page":"497","DOI":"10.4161\/mabs.20452","volume":"4","author":"D Schlatter","year":"2012","unstructured":"Schlatter D, Brack S, Banner DW, Batey S, Benz J, Bertschinger J, Huber W, Joseph C, Rufer AC, van der Klooster A et al (2012) Generation, characterization and structural data of chymase binding proteins based on the human Fyn kinase SH3 domain. mAbs 4:497\u2013508","journal-title":"mAbs"},{"key":"386_CR82","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.pep.2004.09.016","volume":"39","author":"HU Schmoldt","year":"2005","unstructured":"Schmoldt HU, Wentzel A, Becker S, Kolmar H (2005) A fusion protein system for the recombinant production of short disulfide bond rich cystine knot peptides using barnase as a purification handle. Protein Expr Purif 39:82\u201389","journal-title":"Protein Expr Purif"},{"key":"386_CR83","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.jaci.2007.04.028","volume":"120","author":"L Schneider","year":"2007","unstructured":"Schneider L, Lumry W, Vegh A, Williams AH, Schmalbach T (2007) Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. J Allergy Clin Immunol 120:416\u2013422","journal-title":"J Allergy Clin Immunol"},{"key":"386_CR84","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nri3916","volume":"15","author":"G Screaton","year":"2015","unstructured":"Screaton G, Mongkolsapaya J, Yacoub S, Roberts C (2015) New insights into the immunopathology and control of dengue virus infection. Nat Rev Immunol 15:745\u2013759","journal-title":"Nat Rev Immunol"},{"key":"386_CR85","first-page":"297","volume":"5","author":"DK Shah","year":"2013","unstructured":"Shah DK, Betts AM (2013) Antibody biodistribution coefficients. mAbs 5:297\u2013305","journal-title":"Antibody biodistribution coefficients. mAbs"},{"key":"386_CR86","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0076-6879(00)28406-1","volume":"328","author":"SS Sidhu","year":"2000","unstructured":"Sidhu SS, Lowman HB, Cunningham BC, Wells JA (2000) Phage display for selection of novel binding peptides. Methods Enzymol 328:333\u2013363","journal-title":"Methods Enzymol"},{"key":"386_CR87","doi-asserted-by":"crossref","first-page":"14392","DOI":"10.1074\/jbc.M113.534578","volume":"289","author":"M Silacci","year":"2014","unstructured":"Silacci M, Baenziger-Tobler N, Lembke W, Zha W, Batey S, Bertschinger J, Grabulovski D (2014) Linker length matters, Fynomer-Fc fusion with an optimized linker displaying picomolar IL-17A inhibition potency. J Biol Chem 289:14392\u201314398","journal-title":"J Biol Chem"},{"key":"386_CR88","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/19420862.2015.1093266","volume":"8","author":"M Silacci","year":"2016","unstructured":"Silacci M, Lembke W, Woods R, Attinger-Toller I, Baenziger-Tobler N, Batey S, Santimaria R, von der Bey U, Koenig-Friedrich S, Zha W et al (2016) Discovery and characterization of COVA322, a clinical-stage bispecific TNF\/IL-17A inhibitor for the treatment of inflammatory diseases. mAbs 8:141\u2013149","journal-title":"mAbs"},{"key":"386_CR89","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1038\/nbt1166","volume":"23","author":"J Silverman","year":"2005","unstructured":"Silverman J, Liu Q, Bakker A, To W, Duguay A, Alba BM, Smith R, Rivas A, Li P, Le H et al (2005) Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains. Nat Biotechnol 23:1556\u20131561","journal-title":"Nat Biotechnol"},{"key":"386_CR90","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/1099-1352(200007\/08)13:4<167::AID-JMR502>3.0.CO;2-9","volume":"13","author":"A Skerra","year":"2000","unstructured":"Skerra A (2000) Engineered protein scaffolds for molecular recognition. J Mol Recognit 13:167\u2013187","journal-title":"J Mol Recognit"},{"key":"386_CR91","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1111\/j.1742-4658.2008.06439.x","volume":"275","author":"A Skerra","year":"2008","unstructured":"Skerra A (2008) Alternative binding proteins: anticalins - harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities. FEBS J 275:2677\u20132683","journal-title":"FEBS J"},{"key":"386_CR92","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2147\/TCRM.S4438","volume":"5","author":"HS Smith","year":"2009","unstructured":"Smith HS, Deer TR (2009) Safety and efficacy of intrathecal ziconotide in the management of severe chronic pain. Ther Clin Risk Manag 5:521\u2013534","journal-title":"Ther Clin Risk Manag"},{"key":"386_CR93","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1021\/bc010003g","volume":"12","author":"BJ Smith","year":"2001","unstructured":"Smith BJ, Popplewell A, Athwal D, Chapman AP, Heywood S, West SM, Carrington B, Nesbitt A, Lawson AD, Antoniw P et al (2001) Prolonged in vivo residence times of antibody fragments associated with albumin. Bioconjug Chem 12:750\u2013756","journal-title":"Bioconjug Chem"},{"key":"386_CR94","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7150\/thno.13502","volume":"6","author":"J Sorensen","year":"2016","unstructured":"Sorensen J, Velikyan I, Sandberg D, Wennborg A, Feldwisch J, Tolmachev V, Orlova A, Sandstrom M, Lubberink M, Olofsson H et al (2016) Measuring HER2-receptor expression in metastatic breast cancer using [68Ga]ABY-025 Affibody PET\/CT. Theranostics 6:262\u2013271","journal-title":"Theranostics"},{"issue":"724\u2013732","key":"386_CR95","first-page":"e722","volume":"158","author":"EH Souied","year":"2014","unstructured":"Souied EH, Devin F, Mauget-Fa\u00ffsse M, Kol\u00e1\u0159 P, Wolf-Schnurrbusch U, Framme C, Gaucher D, Querques G, Stumpp MT, Wolf S (2014a) Treatment of exudative age-related macular degeneration with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I\/II study. Am J Ophthalmol 158(724\u2013732):e722","journal-title":"Am J Ophthalmol"},{"issue":"724\u2013732","key":"386_CR96","first-page":"e722","volume":"158","author":"EH Souied","year":"2014","unstructured":"Souied EH, Devin F, Mauget-Faysse M, Kolar P, Wolf-Schnurrbusch U, Framme C, Gaucher D, Querques G, Stumpp MT, Wolf S et al (2014b) Treatment of exudative age-related macular degeneration with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I\/II study. Am J Ophthalmol 158(724\u2013732):e722","journal-title":"Am J Ophthalmol"},{"key":"386_CR97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2471\/BLT.16.178061","volume":"95","author":"E Sparrow","year":"2017","unstructured":"Sparrow E, Friede M, Sheikh M, Torvaldsen S (2017) Therapeutic antibodies for infectious diseases. Bull World Health Org 95:1\u201381","journal-title":"Bull World Health Org"},{"key":"386_CR98","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2014.02.528","volume":"63","author":"EA Stein","year":"2014","unstructured":"Stein EA, Kasichayanula S, Turner T, Kranz T, Arumugam U, Biernat L, Lee J (2014) LDL cholesterol reduction with BMS-962476, an adnectin inhibitor of PCSK9: results of a single ascending dose study. J Am Coll Cardiol 63:2889\u20132934","journal-title":"J Am Coll Cardiol"},{"key":"386_CR99","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrc2394","volume":"8","author":"K Strebhardt","year":"2008","unstructured":"Strebhardt K, Ullrich A (2008) Paul Ehrlich\u2019s magic bullet concept: 100 years of progress. Nat Rev Cancer 8:473\u2013480","journal-title":"Nat Rev Cancer"},{"key":"386_CR100","doi-asserted-by":"crossref","first-page":"711","DOI":"10.3390\/ph8040711","volume":"8","author":"JP Tam","year":"2015","unstructured":"Tam JP, Wang S, Wong KH, Tan WL (2015) Antimicrobial peptides from plants. Pharmaceuticals (Basel) 8:711\u2013757","journal-title":"Pharmaceuticals (Basel)"},{"key":"386_CR101","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1073\/pnas.1519960113","volume":"113","author":"K Thell","year":"2016","unstructured":"Thell K, Hellinger R, Sahin E, Michenthaler P, Gold-Binder M, Haider T, Kuttke M, Liutkeviciute Z, Goransson U, Grundemann C et al (2016) Oral activity of a nature-derived cyclic peptide for the treatment of multiple sclerosis. Proc Natl Acad Sci USA 113:3960\u20133965","journal-title":"Proc Natl Acad Sci USA"},{"key":"386_CR102","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1158\/1078-0432.CCR-10-1411","volume":"17","author":"AW Tolcher","year":"2011","unstructured":"Tolcher AW, Sweeney CJ, Papadopoulos K, Patnaik A, Chiorean EG, Mita AC, Sankhala K, Furfine E, Gokemeijer J, Iacono L et al (2011) Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin. Clin Cancer Res 17:363\u2013371","journal-title":"Clin Cancer Res"},{"key":"386_CR103","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S1359-6446(05)03575-0","volume":"10","author":"FM Veronese","year":"2005","unstructured":"Veronese FM, Pasut G (2005) PEGylation, successful approach to drug delivery. Drug Discov Today 10:1451\u20131458","journal-title":"Drug Discov Today"},{"key":"386_CR104","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1126\/science.287.5461.2229","volume":"287","author":"RG Walker","year":"2000","unstructured":"Walker RG, Willingham AT, Zuker CS (2000) A Drosophila mechanosensory transduction channel. Science 287:2229\u20132234","journal-title":"Science"},{"key":"386_CR105","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1525-1403.2006.00055.x","volume":"9","author":"MS Wallace","year":"2006","unstructured":"Wallace MS, Charapata SG, Fisher R, Byas-Smith M, Staats PS, Mayo M, McGuire D, Ellis D, The Ziconotide Nonmalignant Pain Study, G. (2006) Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo-controlled clinical trial. Neuromodulation 9:75\u201386","journal-title":"Neuromodulation"},{"key":"386_CR106","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0304-3959(99)00197-9","volume":"84","author":"YX Wang","year":"2000","unstructured":"Wang YX, Pettus M, Gao D, Phillips C, Scott Bowersox S (2000) Effects of intrathecal administration of ziconotide, a selective neuronal N-type calcium channel blocker, on mechanical allodynia and heat hyperalgesia in a rat model of postoperative pain. Pain 84:151\u2013158","journal-title":"Pain"},{"key":"386_CR107","first-page":"155","volume":"10","author":"UH Weidle","year":"2013","unstructured":"Weidle UH, Auer J, Brinkmann U, Georges G, Tiefenthaler G (2013) The emerging role of new protein scaffold-based agents for treatment of cancer. Cancer Genom Proteom 10:155\u2013168","journal-title":"Cancer Genom Proteom"},{"key":"386_CR108","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/10611860600648254","volume":"14","author":"M Werle","year":"2006","unstructured":"Werle M, Schmitz T, Huang H-L, Wentzel A, Kolmar H, Bernkop-Schn\u00fcrch A (2006) The potential of cystine-knot microproteins as novel pharmacophoric scaffolds in oral peptide drug delivery. J Drug Target 14:137\u2013146","journal-title":"J Drug Target"},{"key":"386_CR109","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S1473-0502(03)00170-8","volume":"29","author":"A Williams","year":"2003","unstructured":"Williams A, Baird LG (2003) DX-88 and HAE: a developmental perspective. Transfus Apher Sci 29:255\u2013258","journal-title":"Transfus Apher Sci"},{"key":"386_CR110","doi-asserted-by":"crossref","first-page":"5620","DOI":"10.1002\/anie.201200984","volume":"51","author":"CT Wong","year":"2012","unstructured":"Wong CT, Rowlands DK, Wong CH, Lo TW, Nguyen GK, Li HY, Tam JP (2012) Orally active peptidic bradykinin B1 receptor antagonists engineered from a cyclotide scaffold for inflammatory pain treatment. Angew Chem Int Ed Engl 51:5620\u20135624","journal-title":"Angew Chem Int Ed Engl"},{"key":"386_CR111","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1158\/1535-7163.MCT-15-0252","volume":"14","author":"J Xiang","year":"2015","unstructured":"Xiang J, Hurchla MA, Fontana F, Su X, Amend SR, Esser AK, Douglas GJ, Mudalagiriyappa C, Luker KE, Pluard T et al (2015) CXCR4 protein epitope mimetic antagonist POL5551 disrupts metastasis and enhances chemotherapy effect in triple-negative breast cancer. Mol Cancer Ther 14:2473\u20132485","journal-title":"Mol Cancer Ther"},{"key":"386_CR112","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1096\/fj.02-1044fje","volume":"17","author":"S Zhu","year":"2003","unstructured":"Zhu S, Darbon H, Dyason K, Verdonck F, Tytgat J (2003) Evolutionary origin of inhibitor cystine knot peptides. FASEB J 17:1765\u20131767","journal-title":"FASEB J"}],"container-title":["Protein &amp; Cell"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13238-017-0386-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13238-017-0386-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13238-017-0386-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T06:44:12Z","timestamp":1676357052000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/proteincell\/article\/9\/1\/3\/6768229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,7]]},"references-count":112,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["386"],"URL":"https:\/\/doi.org\/10.1007\/s13238-017-0386-6","relation":{},"ISSN":["1674-800X","1674-8018"],"issn-type":[{"value":"1674-800X","type":"print"},{"value":"1674-8018","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,7]]}}}